A phase I, randomized, placebo-controlled trial testing inebilizumab, an anti-CD19 monoclonal antibody in 28 SSc patients (24 in inebilizumab and 4 in the placebo group), has shown a depletion of peripheral B and plasma cells, with a possible effect on skin fibrosis (mRSS), but 2 serious adverse effects in the inebilizumab group led to the discontinuation of the trial (116). Here, CD19 is linked to systemic sclerosis.